Leerink Partnrs Predicts Zoetis’ FY2025 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Zoetis in a research note issued to investors on Monday, October 13th. Leerink Partnrs analyst D. Clark now forecasts that the company will earn $6.32 per share for the year, down from their prior estimate of $6.37. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ FY2026 earnings at $6.81 EPS, FY2027 earnings at $7.27 EPS and FY2028 earnings at $7.73 EPS.

Other research analysts have also issued research reports about the stock. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $196.71.

Zoetis Stock Down 1.0%

Zoetis stock opened at $142.08 on Wednesday. The firm has a market cap of $62.97 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 2.30 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The firm has a fifty day moving average price of $148.89 and a two-hundred day moving average price of $154.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is currently 34.42%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ZTS. Nova Wealth Management Inc. acquired a new position in shares of Zoetis during the first quarter valued at about $25,000. 1248 Management LLC bought a new stake in Zoetis in the first quarter valued at about $27,000. Saudi Central Bank bought a new stake in Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the period. Finally, REAP Financial Group LLC increased its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.